Yizun Biomedical
Latest round
- Series A
Last raised
- Apr 2024
Total raised
- $14M
Investors
- 9
About Yizun Biomedical
Established in 2018 and based in Hangzhou, China, Yizun Biomedical is dedicated to developing innovative cell therapies for cancer treatment. The company originated from the Fred Hutchinson Cancer Research Center and the University of Washington and was officially founded in Shanghai the same year. Yizun has established a significant presence with a research and development base in Hangzhou and has expanded its operations with a GMP-standard production facility. Under the leadership of the founder Dr. Liu Lingfeng, the company has built a team of experts with extensive experience in the field. Yizun has forged strategic partnerships with renowned institutions such as Zhejiang University School of Medicine Affiliated First Hospital and Fujian Provincial Tumor Hospital, among others, to advance its clinical research and development efforts. The company specializes in the development of cell therapies based on its proprietary CNK-T, VAC-T, and U-T technology platforms. The CNK-T platform is designed to overcome the immune suppression barrier in solid tumors, while VAC-T enhances the internalization and presentation of tumor or viral antigens. The U-T platform ensures the safety and timeliness of allogeneic cell therapy, enabling scaling production and standardized treatment. These therapies are aimed at treating a wide range of solid and blood tumors, as well as autoimmune diseases and viral infections. The company generates revenue by providing innovative cell therapy products and services, focusing on the development and potential commercialization of treatments for various types of cancer and immune-related conditions.
Who invested in Yizun Biomedical
9 investors across 3 rounds
See all investors in Yizun Biomedical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Yizun Biomedical
Who invested in Yizun Biomedical?
Yizun Biomedical has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Yizun Biomedical raised?
Yizun Biomedical has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Yizun Biomedical last raise money?
Yizun Biomedical's most recent round on record is a Series A, in Apr 2024.
What does Yizun Biomedical do?
Established in 2018 and based in Hangzhou, China, Yizun Biomedical is dedicated to developing innovative cell therapies for cancer treatment.
Where is Yizun Biomedical headquartered?
Yizun Biomedical is headquartered in Hangzhou, China.
Which VCs invest in companies like Yizun Biomedical?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Yizun Biomedical's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Yizun Biomedical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.